Role of Liraglutide in a Major Complication of Diabetes: A Critical Review of Clinical Studies

Diabetes is a most common, serious and chronic illness resultant from the error of insulin secretions or action. Liraglutide is a synthetic glucagon-like peptide-1 receptor agonist (GLP-1 RA) that shares 97% of homology with the glucagon-like peptide-1 (GLP-1) human structure. It acquires a muchextended circulating half-life. Including of numerous in-vitro and in vivo studies explaining the liraglutide efficiency on diabetes, however, various preclinical and clinical studies representing the potential benefit of liraglutide in other complicated diseases induced by diabetes. The therapeutic conclusion of liraglutide in association with other difficulties generated in diabetic patients is complex and includes numerous positive roles. So, there is a necessity of clinical studies to clarify the roles of liraglutide in other complications caused by diabetes. In the coming time, liraglutide uses lonely or in combination may be the predictable approach in the successful management of other diabetes tempted complications. The aim of this review is to collect evidence on the real-world clinical efficiency of liraglutide on main diseases created by diabetes. In present study, results from electronically searchable data are included from randomized clinical studies, cohort studies, clinical trials in addition to other related articles.